The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study.

Tyrosine kinase inhibitors increased disease-specific survival both for new and prevalent chronic myeloid leukemia cases. The effectiveness was similar to that observed in trials only in patients ages 65 years or younger.